Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure

IMPORTANCE: In 2015, the US Food and Drug Administration approved 2 new medications for treatment of heart failure with reduced ejection fraction, sacubitril/valsartan and ivabradine. However, few national data are available examining their contemporary use and associated costs. OBJECTIVE: To evalua...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Cardiol
Päätekijät: Sumarsono, Andrew, Vaduganathan, Muthiah, Ajufo, Ezimamaka, Navar, Ann Marie, Fonarow, Gregg C., Das, Sandeep R., Pandey, Ambarish
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2020
Aiheet:
Brief Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865331/
https://ncbi.nlm.nih.gov/pubmed/31738371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2019.4982
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia